Abstract Purpose of Review Ischemic cardiomyopathy refers to systolic left ventricular
dysfunction in the setting of obstructive coronary artery disease and represents the most …

Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …

Background: SGLT2i (sodium-glucose cotransporter-2 inhibitors) improve clinical outcomes
in patients with heart failure, but the mechanisms of action are not completely understood …

Background: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction
are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin …

ST-segment elevation myocardial infarction (STEMI) remains a significant source of
morbidity and mortality worldwide. Despite advances in treatment leading to a significant …

The significant reduction in 'ischemic time'through capillary diffusion of primary
percutaneous intervention (pPCI) has rendered myocardial-ischemia reperfusion injury …

Aims Left ventricular (LV) remodelling after acute myocardial infarction (AMI) is associated
with heart failure and increased mortality. There was no consensus on the definition of LV …

Background Reliable predictors of treatment efficacy in heart failure have been long
awaited. DNA damage has been implicated as a cause of heart failure. Objectives The …

Post-ischemic left ventricular (LV) remodeling is a biologically complex process involving
myocardial structure, LV shape, and function, beginning early after myocardial infarction (MI) …

Patients with ST elevation myocardial infarction (STEMI) are at risk of future heart failure
(HF), particularly those with anterior STEMI. Interleukin-1 (IL-1) is a key mediator of the …